Abstract: Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, and their immune related adverse events (irAEs) are receiving increasing attention. Among these irAEs , ICIs-associated myocarditis is relatively rare, but the mortality rate is extremely high. Early diagnosis and intervention are beneficial for minimizing the cardiac toxicity of ICIs, and then improving patient prognosis. The role of non-invasive imaging methods in the diagnosis of ICIs-associated myocarditis is crucial. The authors aim to review the epidemiology of ICIs-associated cardiotoxicity, the possible mechanisms, clinical manifestations, the diagnosis status, non-invasive imaging methods and research progress of ICIs-associated myocarditis. Aiming at increasing the clinician’s awareness of ICIs-associated myocarditis and further undestanding the imaging methods for ICIs-associated myocarditis.